| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Outline of Final Research Achievements |
Airway viral infections cause the exacerbations of obstructive lung diseases. B7-H1/PD-L1 is an immune-checkpoint molecule that plays a role in an escape mechanism of viruses from the host immune systems. This escape may be associated with the persistence of viral infection and the exacerbation of the underlying diseases. In a study in vitro, we have shown that a PI3-kinase-delta inhibitor attenuated the upregulation of B7-H1/PD-L1 on airway epithelial cells stimulated with an analog of viral double-stranded(ds) RNA. In this study, we investigated the effect of PI3-kinase inhibitor on the expression of B7-H1/PD-L1 in dsRNA-induced inflammation in mice. Administration of dsRNA upregulated the expression of B7-H1/PD-L1 and induced neutrophilic inflammation, which were suppressed by pretreatment with the PI3-kinase inhibitor. These results suggest PI3-kinase-delta inhibitor as a candidate of clinical use for preventing the virus-induced exacerbations of obstructive lung diseases.
|
